TP53 and lung adenocarcinoma: Based on the genomic, transcriptomic, proteomic, and clinical cancer database in non-small cell lung cancer and lung adenocarcinoma, patients with TP53 mutations, or Mut-p53-related EMT phenotypes have higher PD-L1 mRNA expression and low levels of miR-34/miR-200 (23, 78, 79).